Epirubicin hydrochloride is under clinical development by NanoCarrier and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Epirubicin hydrochloride’s likelihood of approval (LoA) and phase transition for Soft Tissue Sarcoma took place on 23 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Epirubicin hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Epirubicin hydrochloride overview

Epirubicin hydrochloride (pH-sensitive micelles, NC-6300, Epirubicin Micelle) is under development for the treatment of soft tissue sarcoma and angiosarcoma. The drug candidate is administered by intravenous route. It acts by targeting topoisomerase II. It is an anthracycline drug. It is a controlled release nanoparticle formulation. It was also under development for the treatment of solid tumours.

NanoCarrier overview

NanoCarrier is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s pipeline products include NC-6004, VB-111, ENT103, NC-6004, NC-6300, NC-6100, TUG1 and RUNX1. NanoCarrier’s NC-6004 is used for the treatment for pancreatic cancer, head and neck cancer, bladder cancer, and biliary tract cancer. The company’s VB-111 is used for the treatment of recurrent glioblastoma, ovarian cancer and thyroid cancer. Its micellar nanoparticle technology is also used in developing cosmetics and healthcare products. The company operates its laboratory in Kanagawa, Japan. NanoCarrier is headquartered in Tokyo, Japan.

Quick View Epirubicin hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Epirubicin hydrochloride
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.